Baseline characteristics
| Total N=98 | Metal stent N=31 (31.6%) | Plastic stent N=43 (43.9%) | Preoperative plastic stent N=24 (24.5%) | p Value | |
|---|---|---|---|---|---|
| Age* | 66.5±11.2 (34–88) | 66.4±11.3 (34–87) | 66.8±11.5 (45–88) | 66.0±11.1 (46–84) | 0.9613 |
| Gender, N (%) | 0.2062 | ||||
| Female | 37 (37.8) | 15 (48.4) | 16 (37.2) | 6 (25) | |
| Male | 61 (62.2) | 16 (51.6) | 27 (62.8) | 18 (75) | |
| Race, N (%) | 0.2700 | ||||
| Caucasian | 74 (75.5) | 25 (80.7) | 29 (67.4) | 20 (83.3) | |
| African-American | 21 (21.4) | 6 (19.4) | 11 (26.2) | 4 (16.7) | |
| Other | 3 (3.1) | – | 3 (7.1) | – | |
| Diagnosis, N (%) | <0.0001† | ||||
| Pancreatic cancer | 57 (56.4) | 26 (83.9) | 16 (37.2) | 13 (54.2) | |
| Cholangiocarcinoma | 17 (16.8) | 1 (3.2) | 8 (18.6) | 8 (33.3) | |
| Other | 27 (26.7)‡ | 4 (12.9) | 19 (44.2) | 3 (12.5) | |
| Chemoradiation, N (%) | 0.0160† | ||||
| Prior | 8 (8.2) | 1 (3.2) | 7 (16.3) | – | |
| Current | 11 (11.2) | 4 (12.9) | 7 (16.3) | – | |
| Restent, N(%) | 27 (27.6) | 6 (19.4) | 18 (41.9) | 3 (12.5) | 0.0168† |
| Number of restenting session, N(%) | 0.1639 | ||||
| 1 | 21 (21.4) | 6 (19.4) | 12 (27.9) | 3 (12.5) | |
| 2 | 3 (3.1) | – | 3 (7.0) | – | |
| ≥3 | 3 (3.1) | – | 3 (7.0) | – | |
| Karnofsky score§ | 80 (20–100) | 80 (80–100) | 65 (20–80) | 80 (80–100) | <0.0001† |
| Liver metastases, N (%) | 16 (16.3) | – | 16 (37.2) | – | <0.0001† |
| Other metastases, N (%) | 18 (18.4) | 3 (9.7) | 15 (35.7) | – | 0.0019† |
| Whipple resection, N (%) | 21 (21.4) | 5 (16.1) | – | 16 (66.7) | <0.0001† |
| Death, N (%) | 90 (91.8) | 29 (93.6) | 43 (100) | 18 (75) | 0.0015† |
*Mean±SD (range).
†Significant result at the 0.05 level of significance.
‡Metastatic lung cancer (5), metastatic colon cancer (4), metastatic breast cancer (3), gallbladder cancer (3) lymphoma (4), metastatic cancer to lymph nodes of unknown source (8).
§Median (range).